Zoetis (ZTS) Stock Forecast & Price Target

$164.28 -0.90 (-0.54%)

Closing price 03:59 PM Eastern

Extended Trading

$160.22 -4.06 (-2.47%)

As of 06:13 PM Eastern

Zoetis - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 12 Analyst Ratings

Sell
0

Hold
1

Buy
11

Based on 12 Wall Street analysts who have issued ratings for Zoetis in the last 12 months, the stock has a consensus rating of "Buy." Out of the 12 analysts, 1 has given a hold rating, 9 have given a buy rating, and 2 have given a strong buy rating for ZTS.

Consensus Price Target

$215.90
31.43% Upside

According to the 12 analysts' twelve-month price targets for Zoetis, the average price target is $215.90. The highest price target for ZTS is $244.00, while the lowest price target for ZTS is $180.00. The average price target represents a forecasted upside of 31.43% from the current price of $164.28.

Get the Latest News and Ratings for ZTS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Zoetis and its competitors.

ZTS Analyst Ratings Over Time

Type	Current Forecast 3/18/24 to 3/18/25	1 Month Ago 2/17/24 to 2/16/25	3 Months Ago 12/19/23 to 12/18/24	1 Year Ago 3/19/23 to 3/18/24
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	9 Buy rating(s)	9 Buy rating(s)	8 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$215.90	$215.40	$216.70	$224.33
Forecasted Upside	31.43% Upside	36.73% Upside	29.75% Upside	31.44% Upside
Consensus Rating	Buy	Buy	Buy	Buy

Remove Ads

ZTS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ZTS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Zoetis Stock vs. The Competition

Type	Zoetis	Medical Companies	S&P 500
Consensus Rating Score	3.08	2.82	2.54
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	31.43% Upside	22,453.45% Upside	18.80% Upside
News Sentiment Rating	Positive News See Recent ZTS News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
2/27/2025	Piper Sandler 2 of 5 stars	David Westenberg Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$200.00 ➝ $205.00	+24.25%
2/14/2025	Barclays 3 of 5 stars	Balaji Prasad Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$242.00 ➝ $244.00	+52.72%
2/14/2025	Morgan Stanley 3 of 5 stars	Erin Wright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$243.00 ➝ $238.00	+49.95%
1/7/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$210.00 ➝ $180.00	+9.13%
12/9/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$196.00	+10.04%
12/2/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Clark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
12/2/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$215.00	+22.68%
10/11/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$225.00 ➝ $230.00	+20.70%
8/12/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Massaro Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$220.00 ➝ $225.00	+22.75%
8/9/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Hellweg Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
Get the Latest News and Ratings for ZTS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Zoetis and its competitors with MarketBeat's FREE daily newsletter.
5/8/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$230.00 ➝ $225.00	+36.80%
5/6/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$223.00 ➝ $196.00	+17.58%
12/19/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	$230.00	+16.03%
12/7/2023	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$237.00	+30.22%
4/11/2023	Bank Of America (Bofa) Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$180.00 ➝ $200.00	+16.74%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 10:33 PM ET.

Should I Buy Zoetis Stock? ZTS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, March 17, 2025. Please send any questions or comments about these Zoetis pros and cons to contact@marketbeat.com.

Zoetis
Bull Case

Here are some ways that investors could benefit from investing in Zoetis Inc.:

Zoetis Inc. has demonstrated strong financial performance, reporting earnings per share of $1.40, which exceeded analysts' expectations, indicating robust profitability and effective management.
The current stock price is $164.65, reflecting a solid market position and investor confidence, which can be attractive for potential investors looking for stable growth.
Institutional investors hold a significant 92.80% of the company's stock, suggesting strong confidence from large financial entities in Zoetis Inc.'s future prospects.
The company has a high return on equity of 53.82%, indicating efficient use of shareholders' equity to generate profits, which is a positive sign for investors.
Recent insider trading activity shows that executives are actively managing their shares, with notable transactions indicating confidence in the company's future performance.

Zoetis
Bear Case

Investors should be bearish about investing in Zoetis Inc. for these reasons:

The stock has experienced a decrease in ownership by some insiders, which could signal a lack of confidence in the company's short-term performance.
Despite a strong market capitalization of $73.73 billion, the price-to-earnings ratio of 30.12 may indicate that the stock is overvalued compared to its earnings, which could deter value-focused investors.
The company has a debt-to-equity ratio of 1.09, suggesting that it has a relatively high level of debt compared to equity, which could pose risks in times of economic downturns.
Recent fluctuations in stock price, with a 52-week range from $144.80 to $200.33, may indicate volatility that could be concerning for risk-averse investors.
While the company has shown growth, the PEG ratio of 2.78 suggests that the stock may not be growing fast enough relative to its price, which could be a red flag for growth investors.

ZTS Forecast - Frequently Asked Questions

: According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Zoetis is $215.90, with a high forecast of $244.00 and a low forecast of $180.00.
: 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last twelve months. There is currently 1 hold rating, 9 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZTS shares.
: According to analysts, Zoetis's stock has a predicted upside of 31.43% based on their 12-month stock forecasts.
: Zoetis has been rated by research analysts at Barclays, Morgan Stanley, Piper Sandler, and Stifel Nicolaus in the past 90 days.
: Analysts like Zoetis more than other "medical" companies. The consensus rating for Zoetis is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ZTS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:ZTS) was last updated on 3/18/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zoetis (ZTS) Stock Forecast & Price Target